Studies whether SGLT2 inhibitors affect anemia in people with chronic kidney disease
Observes whether SGLT2 inhibitor drugs affect anemia in adults with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Effect of SGLT2 Inhibitors on Anemic CKD Patients
Key facts
- Where
- Sohag, EgyptSee the site
Where in Egypt
- Sohag University HospitalSohag, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sohag University
- Trial code
- NCT07334145
- Record updated
- 14 January 2026
- Original description
anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKDRead full original descriptionShow less
Effect of SGLT2 Inhibitors On Anemia in Patients With Chronic Kidney Disease (CKD)
anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD
Inclusion: age more than 18 years; CKD stage 1_4; baseline hemoglobin 8.5 to 12.9 g/dl; stable anemia regimen for more than 8 weeks.
Exclusion: dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion.